SB 216763

Overview

SB 216763 is potent, selective and ATP-competitive GSK-3 inhibitor with IC 50 s of 34.3 nM for both GSK-3α and GSK-3β .

Application

Products | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Depression | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Obesity | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Autophagy | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > GSK-3 | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-12012
• CAS No.: 280744-09-4
• Molecular Formula: C19H12Cl2N2O2
• Molecular Weight: 371.22
• Purity: 99.76%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution
• Availability: In-stock

Source

Original product source